| Ytd | -2.58% | |
| 1y | 74.19% |
| Open | 74.48 | Prev Close | 74.48 | Low | 73.56 | High | 75.28 | Mkt Cap | 14.60B |
| Vol | 2.97M | Avg Vol | 3.16M | EPS | -3.74 | P/E | N/A | Forward P/E | 141.33 |
| Beta | 0.97 | Short Ratio | 9.07 | Inst. Own | 103.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 68.73 | 200-d Avg | 68.28 | 1yr Est | 102.28 |
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st
- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre
BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers t
Canaccord Genuity analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 202
Citigroup analyst Eric Joseph initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Neutral
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstr
New data demonstrating disease modifying effects across clinical outcomes, biomarkers, and functiona
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with
Evercore ISI Group analyst Cory Kasimov maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperfor
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.84) per share which missed the analy
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of b
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with
Mizuho analyst Salim Syed reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and maintai
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with
RBC Capital analyst Luca Issi initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperf
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceu
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises t
BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease t
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA hig
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory fili
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and rais
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and
Oppenheimer analyst Trevor Allred maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and
Evercore ISI Group analyst Cory Kasimov maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperfor
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(1.00) per share which missed the analy
Ten large-cap stocks sank last week as weak earnings, lowered guidance, analyst downgrades, and deal
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with
Oppenheimer analyst Trevor Allred maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and
Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and
BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceu
Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and
The transaction is part of our strategy to lower interest expense, reduce dilution, and significantl
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilut
- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $36